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A mouse somatostatin (SS) receptor cDNA was cloned from neuroblastoma x glioma (NGI08-15) cells. The sequence isalmost identical to that 
of the mouse SgTR2 r~eeptor [(1992) Proc, Nail, Acad, Sci, USA 89, 251)l bat lacks about 300 nu01eotides between transmembran¢ domain VII 
and the C-terminus. This spliced variant of SSTR2 (designated SSTR2B) encodes a protein which is 23 residues shorter than that predicted from 
the SSTR2 sequence, and differs in 15 amino acids at the C-terminus. mRNA corresponding to SSTR2B occurs in mouse tissues in higher 
abundance than that of SSTR2, SSTR2B binds SS peptides with high aflinit), when expressed in mammalian cells, 
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1. INTRODUCTION 
Somatostatin (SS)-14, and its N-terminal extended 
t~orm SS-28, exert a wide variety of actions in the pitui- 
tat'y, the central nervous ystem, as well as in various 
peripheral tissues [1]. These functions are thought o be 
mediated through G-protein-coupled receptors, which 
results in inhibition of adenylate cyelase, opening of 
potassium channels and closing of calcium channels 
[2,3]. Inhibition of adenylate cyclase by SS peptides has 
been reported in many cell lines. For instance, in the 
mouse neuroblastoma × rat glioma hybrid cell line 
(NGI08-15) SS-14 was found to inhibit prostaglandin 
El-stimulated adenylate cyclase [4]. SS peptides also 
decrease CRH (corticotropin releasing hormone)An- 
duced cAMP levels in pituitary-derived mouse ART-20 
cells. In this cell line SS receptors couple to adenylate 
eyclase via Gi~t [5]. 
Receptor binding studies provided evidence for the 
existence of at least two SS receptor subtypes (SRIFI, 
SRIF2) [6]. Recently, two different SS receptors (SSTR 1 
and SSTR2) have been cloned from human and mouse 
genomic libraries [7]. In addition, the rat homologue of 
the SSTR2 receptor was isolated from a brain eDNA 
library [8]. The pharmacological characteristics of the 
cloned SSTRI receptor were similar to those of the 
SR1F2 receptor, whereas the properties of the other 
cloned receptor (SSTR2) were similar to those of the 
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SR1FI receptor [9]. Southern blot analysis uggests that 
the SS receptor family may comprise two additional 
members [7]. 
In this study we describe the cloning of a novel SS 
receptor eDNA which lacks about 300 nucleotides when 
compared to sequences of mouse and rat SSTR2 [7,8]. 
This spliced variant of SSTR2 (designated SSTR2B) 
encodes a protein which is 23 residues horter than that 
predicted from the SSTR2 sequence, and differs in 15 
amino acids at the C-terminus. mRNA corresponding 
to SSTR2B occurs in mouse tissues in higher abundance 
than that of SSTR2. These results provide evidence for 
a further degree of diversification amongst the SS recep- 
tors at the level of mRNA splicing. 
2. MATERIALS AND METHODS 
2.1. Polymerase chain reaction (PCR ), clot~ing attd sequencCng 
Degenerate primers from transmembrane segments 111 and VI of 
G-protein-coupled receptors [10l were used to amplify a eDNA de- 
rived from mouse neuroblastoma × rat glioma hybrid (NG 108-15)cell 
mRNA. Amplified DNA was cloned into vector pBlueseript (Strat- 
agone, Heidelberg, Germany). Four clones howlng the motif o1" G- 
protein-coupled receptors were obtained. Clone 561-51 was used as a 
probe to screen a AZAP 11 eDNA library eonstrue|¢d from size- 
selected poly(A) ÷ RNA from NGI08-15 cells (custom synthesis by 
Clont~h, Heidelberg, Germany). Three hybridizing plaques were ob- 
tained by screening 1.5 × 10 ~ phages with probe 561-51 under high 
stringency conditions (51CFI, 51CF2, 51CF3). The plasmids were 
excision-rescued from the corresponding AZAP 1I clones by superin- 
feetion with hel~r phages, The clones were sequenced by the chain 
termination method [11], Clone 51CF3-1 contains a 1,9 kb EcoRI 
fragment with a complete sequence of a receptor, with seven trans- 
membrane domains, including 3' and 5' non-translated relier::;. 
2.2. Expresion attd blinding 
A 1.7 l~amHI-EcoRV fragment of the cloned 51CF3-1 eDNA was 
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1 Cn;GAGGTAGTCA'ITGAGC?TTAGGRAGGTCn;ACATGCAC 
85 GGGCCAGGGCACCGTGAAGRTC~G~~C~TACTTA 
17t TC~PTTGCCTTCGATCC~AC~AC~T~CCG~~~GCAGCCA~C~A~GAG~~AG~GCCTCGGG~ACCT~C~A~C~~~~~~ 
267 Cn;GTATGCTGCCGGCCTCTCGGRAAACCAGTITAGGGTA~AGC~CCAC~C~ATAG~C~A~AT~ TGTCAGGTAAGG 
356 AAGCTGGGAGCCCCGGGAGCCACTGCTGAGCGCCAAhCACCCGCT~GCC~C~~CTCC~ACGCCC~C~T~~C~C~ 
449 C~GGTGCTAGAGAACACAGGG~~GCGAG~C~GAGA 
1 M E M S S E Q L Nb G S 
540 GGAA%?T;%%&:~G~-&%ii%AGACGGAGTGGAAAGCAGCC An: GAG A% AGC TCT GAG CAG TTG AAT GGG AGC 
LZ Q V W V S S P F II L NUG S L G P S NUG S N Q T 
619 CAA GTA TGG GTG TCC TCT CCA TTT GAC CTC AAC GGT TCA CT6 GGG CCA AGC AAT GGC TCC AAC CA6 ACC 
35 E P Y Y D M T S N A V L T P 1 Y F V V C V V G 
66% GAG CCA TAC TAC GAC ATG ACA AGC AAC GCC GTC CTC ACG Ti'C ATC TAC TPC Gl'G GTG n;C GTCZ GTC GGG 
58LCGNTLVIYVrLRYAKMKTITN~ 
757 CTG TGC GGC AAC ACG CTG GTC Am TAC GTC ATC CTC CGC TAC GCC AAG ATG AAG ACC ATC ACC AAC ATC 
61 Y I L N L A I A D E L F M L r, L P F L A M 0 y 
826 TAC ATC CTT AAC CTG GCC ATT GCA GAT GAA CTC T'L'C ATG CTA GGG cn; CCC TTC TTG GCC AlG CAG GTG 
104 A L V II W P P G X A I C R V V M T V D G 1 N Q 
895 GCG CTA GTC CAC TGG CCT TTT GGC AAG GCC ATC TGC CGG GTG GTC ATG ACT GTA GAT GGC ATC AAT CAG 
127 P T 9 I P r L T V M S T D R Y L A V V H P I X 
964 TTC ACC ACT ATC TTC TGC TTG ACG GTC An; AGC ATC GAC CGC TAC CTG CCC GTG GTG CAC CCC ATT AAG 
150 S A K W R R P R T A K M I N V A V W C V S L L 
1033 TCA GCC AAA TGG AGG CGA CCC CGG ACA GCC AAG ATG ATC AAT GTG GCT GTG TGG TGT CT6 TCT CTG CTC 
173 V I L P 1 M L Y A G L R S N Q W G R S S C T I 
1102 GTC ATT TTG CCC ATC ATG Tl'A TAC GCC GGC CTC CGG AGC AAC CAG TOG GGC AGA AGC AGC TGT ACC ATC 
196 N W P G E S G A W Y T G P T f Y A F 11. E =L 
1171 AAC TGG CCA GGC GAA TCC GGG GCG TGG TAC ACA GGT TTC hTT ATC TAC CCC TTC ATC Cl% GGG TTC cn; 
219 V P L C I I C L C Y L F I T I K V K S S G I R 
1240 GTA CCC CTT ACC ATC A?"l' TGT CTC TGC TAC C'TG TTC ATC ATC ATC AAG GTG AAG TCC 'i-CT GGA ATC CGA 
242 V G S" S'K R K K S'E K K V T R M V @a 1 V V A V 
1309 GTG GGA TCA TCC AAG AGG AAA AAG TCA GAG AAA AAG GTG ACE CGC ATG GTG TCC ATC GTA G!I'G GCT GTC 
265 P T F P W L P F Y f F N V S G V S V h I S P T 
1378 TTC! ATC TTC TGC TGG CTC CCT Ti'C TAC ATC TTC ARC GTC TCT TCC GTG TCT GTG GCC ATC AGT CCC ACC 
286 P A L K G M F D r . " ILTYANTCANPI 
1447 CCA CCC CTG AAA GGA ATG TTT GAC TTT GTG GTG ATC CTC ACC TAT GCC AAC ACG TGC GCC ARC CCC ATC 
311 L Y A F L S D N P K K S F Q NV L C L V X A D 
1516 CTG TAC GCC TTC TTG TCT GAC AAC TTC AAG AAG AGC TTC CAG AAT GTT CTT TCC TTG GTC AAG GCA GAC 
334 N S* Q S*G A E D I I A W V OPA 
1585 AAT TCA CAA TCC GGA GCG GAA GAC ATC ATT G C\: TGG GTG TGA CCTGGTGGAAAACAGCTGCCCGGCAGAAACCGGAA 
16C2 AAACCAAAACTAAA~C~~~~C~~~~~~~~CT~CACGTTACGTA~TC~~A~~ATAT~ACA~TATA~C~CCC 
1753 TCCCCGGTCACACAAACATGTCCCG~~T~GCCC~GTAGCTAG~CG~~CGTCTAGTATAGG~GACAG~ACCAC~CGC~A 
1884 ACCTGAAGARAAGGACTCGCCACGTCACAGTCAGTCCAATCT 
Fig. I I Nucleotidc and predicted amino acid sequence of the cloned mouse somatostatin receptor cDNA (5lCF3-1). The presumptive transmcm- 
brane domains (I-VII) are underlined and are assigned on the basis of a Kyle and Doolittle hydrophobicity plot [17]. Potential N-linked 
glycosylation sites in the N-terminal region (8) and phosphorylation sites in the C-terminal region and third cytoplasmic loop are indicated (‘). 
Primers used for PCR (SPL4, SPLS) arc marked by dashed lines with arrows. 
inserted into expression vector pcDNAl (Invitrogen, San Diego, 
USA). The resulting vector pcDNAI-51 was transiently expressed in
COS-7 monkey kidney cells using the DEAE-dentran method [I?]. 
For stable xpression, 2yg of the plasmid pcDNAI-51 were co-trans- 
fected with 0. I pg plusmid pcDNAIneo in Chinese hamster ovary cells 
(CHO-KI) with lipofectin (Gibco-BRL, Eggenstcin, Germany) ac- 
cording to the instructions of the manufacturers. Stable transfectants 
were selected in DMEM medium containing 6OOgg (2418 per ml and 
chcckcd for expression by Northern blot analysis. 
For binding measurements, COS-7 cells were grown to 50% conflu- 
ence in 35 mm six-cluster wells and transfectcd. After 48 h, the cells 
were washed with 10 mM HEPES buffer (pH 7.5) and incubated with 
buffer containing IO mM HEPES (pH 7.5), 5 mM KH2P0,. 5 mM 
‘MgtX, I50 mM NaCi and i% (Whj hovino SCiUlil atbumin. 5 mg/ml 
bacitracin, 20,000 cptn [“‘I]Tyr”-SS (Amersham, Braunschweig, Ger- 
many) and the indicated concentrations of SS-14. SS-28 (Saxon Bio- 
chemicals, Hannover, Germany) or SMS 201-995 (Sandoz, Basic. 
Switzerland) for 60 min at room temperature. Thcreaficr the cells were 
washed twice with ice-cold IO mM HEPES buBcr and dissolved in I .S 
ml of 8 M urea/3 M acetic acid. The radioactivity in the dissolved cells 
was measured in a y-counter. 
2.3. RNA csrracrion tntd Norrlwm blorrhg 
Male NMRI mice weighing 25-30 g were killed by decapitation and 
h tissues immediately removed, dissected and placed on dry ico. 
Total RNA was extracted from the tissues by using the acid guanidin- 
ium isothiocyanatclphenol chloroform method 1131. Poly(A) RNA 
was isolated from total RNA using the QuickPrep mRNA purification 
kit from Pharmacia (freiburg. Germany). In addition, RNA was 
extract& from AtT-20/D-W cells (Dr. Kelly, San Francisco, USA), 
NE!08-! 5 cells (Dr. llamprccht. Tubingen. Gcnnany) and GH3cells 
(Dr. Baxter. San Francisco. USA). Aliquots of 3 .ug poly(A) RNA 
were denatured by glyoxal, separald by electrophoresis, lraaafcrrecl 
to nylon supports and hybridizud with radiolabelled single-slranded 
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Fig. 2. Alignment of nudeotide and predicted amino acid sequence of the C-terminal portion of 51CF3-1 eDNA with the mouse SSTR2 8enomic 
sequences and the sequences of rat SSTR2 eDNA. The position of nueleotide differences within the coding regions are indicated by asterisks. The 
8chemic sequence of mouse SSTR2 has not been completely published [7]. The missing nueleotides are indicated by dots. 
cRNA probe. The probe was synthesized with T3 polyraerase and 
[nPIUTP using clone 561.51 as a template and hybridized at co,adi- 
tions previously described [14]. 
2.4 PCR amplification ofcDNAs 
cDNAs were reverse transcribed from RNAs extracted from ART-20 
cells, treated with RNAse.free DNase and subjected to 50 cycles of 
PCR with Taq polymerase [15]. The following primers were used: 
SLP4 (5"-GATCI'C'TAGGCAGCI'TGGTTCT-Y, matching at nucle- 
otides 554--575) and SLP5 (5'.ACACATACACACAGGACTTTGA. 
Y, matchlnB at nucleotldes 1,707-1,686). Cycle conditions were 1 mila 
at 96"C, 1 min at 55°C and 1 rain at 72°C. 
3. RESULTS AND DISCUSSION 
A eDNA was prepared from poly(A) RNA of 
NG108-15 cells and amplified by PCR using degener- 
ated primers corresponding to transmembrane domain 
III and VI according to a protocol previously described 
[10]. 
Nueleotide sequence determination f cloned ampli- 
lied sequences revealed that fragments of the rat endo- 
thelin IA receptor [16] had been amplified. In addition, 
three novel putative receptor-encoding fragments were 
identified (561-8; 561-39; 561-51). Clone 561-51 was 
used to identify full-length cDNAs in a NG108-15 
eDNA library (~ZAP). Three phage 2, clones were ob- 
tained. The largest clone (51CF3-1) contains a 1,901 bp 
EcoRI fragment with an open reading frame of 346 
amino acids (Fig. 1). Hydrophobicity analysis of the 
amino acid sequence indicates even hydrophobic re- 
gions characteristic of G-protein-coupled receptors. 
The protein has potential N-linked glyeosylation sites 
and several serine residues that may provide potential 
phosphorylation sites. Sequence comparison of 51CF3- 
1 with the mouse genomic sequence of a somatostatin 
receptor (SSTR2) published recently [7] shows an al- 
most complete identity up to amino acid 332 (only 
isoleucine at position 180 is replaced by a leueine and 
serine 305 by a threonine). On the other hand, the pro- 
tein predicted from the 51CF3-1 sequence was 23 amino 
acids shorter and differed in the last 15 C-terminal 
amino acids from mouse SSTR2 sequence (Figs. 1 and 
2). Sequence alignment of 51CF3-1 with a recently pub- 
lished eDNA encoding the rat homologue of SSTR2 [8] 
revealed that the mouse DNA clone 51CF3-1 lacks 312 
nueleotides between the bases coding for lysine (332) 
and alanine (333). It is likely that the missing nucleo- 
tides represent an intronic sequence since (i) the junc- 
tions of the putative intronic sequences follow the GT- 
AG rule, (ii) there is a high degree of homology between 
the rat and the mouse DNA sequences downstream of
the intron, and (iii) there is a high homology within the 
slzo marker 
kO 
a b c d e f O I1 i k I 
4.3 
• ; ~ i ' ~ % - : ~  
i i;ii  
- : ' ;~ ,~T,:! '9.0 
Fig. 3. Northern blot analysis of SSTR2 mRNAs in mouse ~!1 lines and tissut~s, as well as in rat GH3 cells. 3.5 fig aliquots el' poly(A) RNA were 
subjected to eleetrophoresis, blotted on nylon membranes and hybridized with ~'~P-labelled 561-51 cRNA probe. HtndIll.digestexl fragment,.; of). 
phage were u~ed as size markers. (a) NGI08-15; (b) liver; (c) testis; (d) striatmn; (e) midbrain; (0 cerebellum; (g) hippocampus; (h) hypothalamus; 
(i) cortex; (k) AtT-20 cells; (1) GH3 cells. 
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Fig. 4. PCR analysis of SSTR2 receptor transcripts in AtT-20 cells. 
PCR with primers corrc+ponding to 5’ and 3’ non-translated regions 
of 5 lCF3-I (SPL4. SPLS. Fig. 1) was carried out on cDNAs synthc- 
sized from At’f-20 RNA. Aliquots corresponding to 500 ng (a). 50 ng 
(b) and 5 ng (c) cDNA were amplified, electrophorescd and stained 
by ethidium bromide. (M) Hbrdlll fragments of A phage and HrrcIIl- 
digested fragments of @xl74 phage wcrc used as she markers. 
intron between the rat cDNA and the published 228 
nucleotides of the mouse gene (Fig. 2). 
To investigate the existence of two forms of SSTR2 
mRNAs (spliced and unspliced) in the mouse, a North- 
ern blot analysis was performed using clone 561-5 1 as 
a probe. As seen in Fig. 3, analysis of poly(A) RNA 
derived from mouse brain areas, AtT-20 cells and 
r 
I 
P I 
Peptide Concentration (hl) 
NG 108-l 5 cells revealed a single band corresponding to 
a mRNA species of 2.3 kb. In contrast, an additional 
mRNA species of 2.6 kb could be visualized in GM3 
cells, a rat pituitary cell line. 
The 2.3 kb mRNA species was found in several brain 
regions, such as cortex, hippocampus, triatum, hypo- 
thalamus and also in the cere’bellum. No SSTR2 mRNA 
was found in the liver and testis. Relatively high levels 
of SSTRZ expression were found in the NGlOS-15 and 
particularly in the AtT-20 cells, a mouse pituitary tumor 
cell line. In order to investigate whether the 2.3 kb 
mRNA species in the mouse tissues corresponds to our 
cloned cDNA we performed PCR experiments. The 
PCR was carried out with a template cDNA con- 
structed from poly(A) RNA derived Dam AtT-20 cells. 
A pair of oligonucleotides matching to a 5’ non-trans- 
lated region (SLP4) and a 3’ non-translated region 
(SPLS) of 5lCF3-1 served as primers (Fig. 1). The gel- 
resolved DNA products comprised two DNA frag- 
ments consistent with the existence of two forms of 
SSTR2 in the mouse tissue (Fig. 4). The shorter DNA 
corresponds to 5lCF3-1 (1,154 bp), whereas the longer 
DNA corresponds to the about 300 nucleotidcs larger 
form of the SSTR2 (1,493 bp). This larger PCR product 
(SISCRI), corresponding to the unspliced form of 
SSTR2, is also seen in PCR amplification of mouse 
genomic DNA (data not shown). When a series dilution 
of cDNAs derived from AtT-20 cells was amplified by 
PCR, the band corresponding to the larger band disap- 
peared at dilutions at which the band of the smaller 
I I ’ I-L__.1 
lo-" 1 o-10 10-g 1o-6 IO-’ 
PepLide Concentration (M) 
Fig. 5. Binding oT[‘XL]Tyr”-SS to cells expressing 5 ICF3-I. (A) COS-7 cells were transiently transfcetcd and the displacement of the hbcllcd ligand 
by SS-I4 and SS-28 has been measurd. Values arc means of triplicate dctcrminadons normalized to percent of maximum binding. (Binding in 
the abscncc of unlabrlied iigdnd was 1900 cpm; in iix presence of iGO II% SS-14 was Xt0 cprn; non-:ra..s.-..., ,- f*td CDS-? cells bind TOO cpm in the 
presence and absence of unlabelled l&and). (B) CHGKI cells wet-c stably trunsfcctcd. The sclcctcd clone, CMO-KI-30, binds 1,800 cpm in the 
absence and 300 cpm in the presence of 100 nM SS-14. The displeccment of1131]Tyr”-SS by SS-14. SS-18 and SMS 101-995 was tncasured. Values 
arc means of triplicate determinations. 
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form was still visible. As judged from the relative abun- 
dance of the PCR products, the smaller form is ex. 
pressed at about 30-fold higher levels in AtT-20 cells 
than the larger form. This low abundance of the larger 
form in mice may explain why only the smaller form of 
the SSTR2 mRNA is detected by Northern blot analysis 
(Fig. 3). 
The situation appears to be different in rat pituitary 
GH3 cells where two mRNA species of 2.3 and 2.6 kb 
of about equal abundance are seen by Northern blot 
analysis (Fig. 3). In addition, similar quantities of both 
the 2.3 and the 2.6 kb form of SSTR2 mRNAs have 
been found in various tissues of the rat by Northern blot 
analysis [8]. It is likely that the larger form represents 
the unspliced form, whereas the smaller mRNA is a 
spliced rat analogue of the SSTR2 mRNA. 
In order to investigate the binding properties of the 
shorter SSTR2 form we transfected the eDNA either 
transiently in COS-7 monkey kidney cells or stably in 
Chinese hamster ovary (CHO) cells. As seen in Fig. 5A 
and B, SS-14, SS-28 and/or the synthetic SS analogue 
SMS 201-995 displaced [~2Sl]Tyrl~-SS- 14 from its newly 
expressed binding sites in COS-7 or ClIO ceils with a 
similar high affinity (ICs0 0.3-0.6 nM). The binding 
affinities of the short of the SSTR2 eDNA for SS-14, 
SS-28 and/or SMS 201-995 appear to be similar to those 
reported for the expressed mouse and rat SSTR2 recep- 
tors [7-91. 
The two SSTR2 differ in amino acid compositions at 
the C-terminal end, a region shown to be important for 
receptor desensitization i volving phosphorylation of 
serine and threonine residues [18]. It is interesting to 
note that the shorter form of the mouse SSTR2 contains 
three serine residues less than the larger form at the 
C-terminal region. Experiments are presently being car- 
ried oat in our group to find out whether the two SSTR2 
receptor forms differ in their desensitization character- 
istics. 
The use of alternate splicing to generate different 
forms was first described for the D2 receptor. Two 
forms of D2 receptors have been identified which differ 
by a 29 residue peptide sequence located in the third 
cytoplasmic loop [19], The larger form has been termed 
D2A and the shorter form the D2B receptor. In analogy 
we propose to designate the longer form of the SSTR2 
receptor as SSTR2A and the shorter form as SSTR2B. 
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